SCHEMBL651135

SCHEMBL651135

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC(F)F)c(F)c1)CC1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
CCR4 P51679 1/20 0.32
CXCR3 P49682 4/20 0.32
HDAC1 Q13547 1/20 0.32
CRHR1 P34998 1/20 0.32
TSHR P16473 2/20 0.32
GRM2 Q14416 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP3A4 P08684 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
BCHE P06276 4/20 0.31
ACHE P22303 1/20 0.31
FNTA P49354 1/20 0.31
FNTB P49356 1/20 0.31
P2RX3 P56373 2/20 0.30
DRD1 P21728 1/20 0.30
DRD4 P21917 1/20 0.30
DRD5 P21918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135694 0.92 C5AR1 (0.44) C5AR1HDAC1CRHR1TSHRKDM4E
SCHEMBL5135166 0.89 C5AR1 (0.45) C5AR1CCR4HDAC1CRHR1TSHR
SCHEMBL650100 0.88 C5AR1 (0.40) C5AR1CCR4HDAC1CRHR1TSHR
SCHEMBL651074 0.88 C5AR1 (0.43) C5AR1CRHR1TSHRGRM2KDM4E
SCHEMBL648763 0.88 C5AR1 (0.40) C5AR1CCR4HDAC1CRHR1TSHR
SCHEMBL650548 0.88 C5AR1 (0.43) C5AR1HDAC1CRHR1TSHRKDM4E
SCHEMBL650600 0.87 C5AR1 (0.39) C5AR1CCR4HDAC1CRHR1TSHR
SCHEMBL651431 0.87 C5AR1 (0.43) C5AR1CCR4HDAC1CRHR1TSHR
SCHEMBL649094 0.87 C5AR1 (0.43) C5AR1CCR4CXCR3HDAC1CRHR1
SCHEMBL650011 0.87 C5AR1 (0.38) C5AR1CCR4HDAC1CRHR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed